Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) reported a fresh share repurchase under its authorised mandate, acquiring 140,000 H-shares on 14 May 2026 via on-market transactions at prices between HKD 3.47 and HKD 3.50. The volume-weighted average repurchase price was HKD 3.4843, bringing total cash outlay to HKD 0.49 million.

Following the transaction, Weigao Group’s issued share capital (excluding treasury shares) declined marginally by 0.0031% to 4.47 billion shares, while the company’s treasury share balance increased to 55.27 million shares. The overall issued share count, including treasury shares, remained unchanged at 4.52 billion.

The repurchase formed part of the mandate approved on 27 May 2025, which permits the company to buy back up to 451.56 million shares. Cumulative repurchases under this authorisation now total 48.62 million shares, equivalent to 10.77% of the issued share base as at the mandate date.

Management confirmed that the buyback complied with all relevant Hong Kong Stock Exchange Main Board Listing Rules. In line with regulatory requirements, Weigao Group is subject to a moratorium on new share issues or treasury-share disposals until 14 June 2026.